TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12765810
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia (rectal temperature 32.0 to 35.0 degrees C)
Study: 12765810
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rectal temperature 36.5 to 37.0 degrees C)
Study: 10834773
Drug: Procaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine (100 mg hyperbaric)
Study: 10834773
Drug: Lidocaine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (50 mg hyperbaric)
Study: 27824753
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg given 1 hour before IUD insertion
Study: 22313793
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3 g/d) and kinako (29 g/d)
Study: 22313793
Drug: Kinako (29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinako (29 g/d)
Study: 24290606
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3 g/d)
Study: 10696629
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acids (5.4 g/d)
Study: 10696629
Drug: sulfasalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfasalazine (2 g/d)
Study: 9356106
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline injection (10 mL) at L2‐3 or L3‐4 interspace 10 min after spinal anesthesia
Study: 9356106
Drug: No epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: No epidural saline injection (Control group)
Study: 2871010
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate 5 mg every 2 weeks
Study: 2871010
Drug: Fluphenazine 5
Normalized name: fluphenazine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluphenazine 5 mg daily
Study: 2871010
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of antipsychotic drugs
Study: 31847348
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) - intermittent use formulation (gum, sprays, inhaler)
Study: 24891337
Drug: FeNO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeNO treatment strategy
Study: 20391859
Drug: Direct person‐to‐person
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct person‐to‐person prayer intervention (six weekly 1-hour sessions)
Study: 16968235
Drug: Average log
Normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average log DNA copy number/ml during clinical stage
Study: 16968235
Drug: Average log
Normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average log DNA copy number/ml during subclinical stage
Study: 8801151
Drug: Prostaglandin F2
Normalized name: Prostaglandin F2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin F2 alpha (20 mg in 20 ml normal saline)
Study: 8801151
Drug: Oxytocin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (30 IU in 20 ml normal saline)
Study: 8801151
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (20 ml)
Study: 1325772
Drug: alpha h‐ANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha h‐ANP (99‐126), 25 micrograms intravenously followed by infusion of 0.1 microgram kg‐1 min‐1
Study: 30497132
Drug: Depomedrol (DEPO)
Normalized name: epomediol
DrugBank: Epomediol (DB13802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depomedrol (DEPO) - 1 ml (80 mg) applied directly to the surgical site
Study: 30497132
Drug: No Depomedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Depomedrol (NODEPO) - 1 ml saline on Gelfoam carrier
Study: 24758565
Drug: DIMS0150 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIMS0150 (30 mg rectal administration)
Study: 17875241
Drug: Alprostadil 5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil 5‐20 microg powder for injection
Study: 16076378
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g sevelamer hydrochloride + 3 g calcium bicarbonate (CaCO3)
Study: 16076378
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g calcium bicarbonate (CaCO3) alone
Study: 12132060
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% plus sufentanil 0.5 microg/mL
Study: 10573104
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 30 mg/day orally for 2 years
Study: 10573104
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 30 mg/day orally for 2 years + UFT 300 mg/day orally for 2 years
Study: 10573104
Drug: UFT 300
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 300 mg/day orally for 2 years
Study: 10573104
Drug: UFT 300
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 300 mg/day orally for 2 years + Tamoxifen (TAM) 30 mg/day
Study: 10573104
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of MMC, TAM, and UFT
Study: 8692031
Drug: CHO trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO trial (150-g x L(‐1) CHO solution)
Study: 8692031
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + MCT trial (70 energy% CHO-30 en% MCT suspension containing 29 g MCT)
Study: 8692031
Drug: HCHO +
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCHO + MCT trial (150-g x L(‐1) CHO solution plus 20 g MCT)
Study: 1858990
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of atropine and 50 mg of meperidine plus oral placebo (n = 14)
Study: 1858990
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral diazepam and intramuscular placebo (2 mL NaCl, concentration = 0.9) (n = 14)
Study: 1858990
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intramuscular placebo (n = 14)
Study: 6356965
Drug: Budesonide (topically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (topically administered glucocorticoid) for 1 week
Study: 30914500
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA supplementation (1.5 g DHA + 0.3 g EPA/day)
Study: 30730860
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin alone
Study: 26941086
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rectal indomethacin and prophylactic pancreatic stent placement (PSP)
Study: 15506067
Drug: rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine 1 mg bid
Study: 10865218
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg once a week (weekly alendronate group)
Study: 10865218
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daily (orally) for 1 month out of 3 (cyclical alendronate group)
Study: 10865218
Drug: Calcium/vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium/vitamin D supplements (control group)
Study: 9124166
Drug: Sotalol 80
Normalized name: sotalol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 80 mg twice daily
Study: 3551508
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg b.i.d.)
Study: 8228077
Drug: H2-antagonist (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-antagonist (single dose)
Study: 8228077
Drug: H2-antagonist (14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-antagonist (14-day chronic dosing)
Study: 8228077
Drug: H2-antagonist (28-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-antagonist (28-day chronic dosing)
Study: 3536469
Drug: Vigabatrin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (1.0 g twice daily for patients ≤ 65 kg; 1.5 g twice daily for patients > 65 kg)
Study: 3042009
Drug: Dithranol +
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithranol + UVB therapy (27 patients)
Study: 26471852
Drug: Stretching and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching and strengthening exercises plus manual therapy
Study: 26471852
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (exercise alone and exercise plus manual therapy)
Study: 23834545
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg kg(‐1))
Study: 18669012
Drug: Empirically adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirically adjusted doses of LMWH
Study: 16679545
Drug: 0.2 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/d sodium selenite in addition to chemotherapy
Study: 12780888
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem (2%) ointment
Study: 12780888
Drug: Glyceryltrinitrate (GTN)
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyceryltrinitrate (GTN) (0.5%) ointment
Study: 9221182
Drug: Consupren at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consupren at an initial dose of 5 mg/kg/d (CS group, n = 16)
Study: 9221182
Drug: Cyclophosphamide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide at a dose of 1.5 mg/kg/d (K group, n = 11)
Study: 1587713
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg all‐rac‐alpha‐tocopherol acetate/kg/d intravenously for 5 days
Study: 2933186
Drug: STK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: STK treatment within 2 hr of onset
Study: 2933186
Drug: STK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: STK treatment after 2 hr of onset
Study: 27161257
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg, three times daily)
Study: 23107220
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin 40 IU q.i.d. (n = 34)
Study: 17445333
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m2 weekly
Study: 17445333
Drug: Vinorelbine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 6 mg/m2 weekly
Study: 12729866
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication (drug trial)
Study: 10629368
Drug: Induction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of labor using oral prostaglandin E(2) at 37 weeks
Study: 7902966
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 out of 3 partial autonomic blockers (indoramin, propranolol, atropine)
Study: 3710284
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc aspartate application during pregnancy
Study: 30483715
Drug: Conventional root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional root canal preparation and calcium hydroxide sealant (Control)
Study: 26065986
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran Etexilate 110 mg
Study: 26065986
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran Etexilate 150 mg
Study: 24035168
Drug: niacin-ER (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin-ER (extended-release niacin) at a maximum of 1,500 mg/day for 12 weeks
Study: 18783622
Drug: RTEC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTEC alone (1 or 2 doses)
Study: 12553385
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anaesthesia (CSA) with prilocaine 2% 40 mg
Study: 12553385
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural anaesthesia (CEA) with prilocaine 1% 150 mg
Study: 18057477
Drug: Phytomenadione (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytomenadione (vitamin K1), 1 mg intramuscularly
Study: 18057477
Drug: Menadione (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menadione (vitamin K3), 1 mg intramuscularly
Study: 9602575
Drug: i.v. morphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. morphine, i.m. diclofenac and intercostal nerve blocks from T2 to T11, 20 min before operation
Study: 9602575
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections before operation, and i.v. morphine, i.m. diclofenac and intercostal nerve blocks from T2 to T11 at the end of surgery
Study: 7767541
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg, four times daily for 16 weeks)
Study: 7767541
Drug: Albuterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (200 micrograms, four times daily for 16 weeks)
Study: 2123142
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition with 15 or 30 kcal/kg.day and 0.30 g of N with standard or branch-chain (BC) enriched AA solutions
Study: 2123142
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition with 30 kcal/kg.day
Study: 2123142
Drug: BCAA-enriched AA
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA-enriched AA solutions
Study: 31855097
Drug: Discussion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discussion of risk factors, prevention strategies, and treatment recommendations.
Study: 25854809
Drug: Home-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based occupational therapy for 10 weeks
Study: 25854809
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (no occupational therapy)
Study: 25476074
Drug: Furosemide therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide therapy, anisodamine, nitroglycerin, beta blocker or cedilanid
Study: 22030597
Drug: Triple-combination treatment
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination treatment (olmesartan medoxomil 40/amlodipine besylate 10/hydrochlorothiazide 25 mg)
Study: 14984936
Drug: Whole pelvic
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole pelvic radiation therapy (RT)
Study: 14984936
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (NAT)
Study: 10402973
Drug: SPf66 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 vaccine (three doses at 1, 2, and 7 months of age)
Study: 2694978
Drug: Thiabendazole 2
Normalized name: Thiabendazole
DrugBank: Thiabendazole (DB00730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiabendazole 2 x 25 mg kg‐1 day‐1
Study: 2694978
Drug: Albendazole 2
Normalized name: albendazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 2 x 5 mg kg‐1 day‐1
Study: 973982
Drug: HSA-Tc 99m
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSA-Tc 99m instilled intranasally as spray
Study: 973982
Drug: HSA-Tc 99m
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSA-Tc 99m instilled intranasally (varied volume 0.10 ml to 0.75 ml, concentration 3% to 30%)
Study: 973982
Drug: Frequent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent administration by drops
Study: 28675091
Drug: Coffee polyphenols
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee polyphenols (CPPs) 270 mg/100 mL/day
Study: 19390480
Drug: 2.7 g
Normalized name: Magnesium 420 MG/2.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 g omega-3 LCPUFA supplementation
Study: 19390480
Drug: 2.8 g
Normalized name: glycerin 2.8 GM per 2.7 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 g soybean oil as placebo
Study: 15324779
Drug: Opioid receptor
Normalized name: Opioid receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid receptor binding in patients with CNP
Study: 8983932
Drug: Droxicam alone
Normalized name: droxicam
DrugBank: Droxicam (DB09215)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxicam alone (20 mg)
Study: 8983932
Drug: Droxicam with
Normalized name: droxicam
DrugBank: Droxicam (DB09215)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxicam with antacid (Mucal powder)
Study: 2921100
Drug: Atenolol (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (long-term treatment)
Study: 27663600
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg twice daily + carboplatin AUC4
Study: 27663600
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 or 200 mg twice daily (days 1-7) + carboplatin AUC4 or 5 every 21 days
Study: 19483074
Drug: poly‐L‐lactic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: poly‐L‐lactic acid polymer tack implants
Study: 19483074
Drug: polygluconate‐B polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: polygluconate‐B polymer tack implants
Study: 19483074
Drug: both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: both implant types
Study: 16508932
Drug: MTX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX plus infliximab (3 mg/kg or 6 mg/kg)
Study: 11079278
Drug: Metoprolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol plus glucagon 1 mg
Study: 9522324
Drug: Transdermal 17‐β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17‐β‐estradiol (50 μg/day)
Study: 26125705
Drug: Zhikang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhikang capsule in addition to conventional dressing changes
Study: 23418154
Drug: Intermittent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent exercise (INT) - 12 hourly, 5-min bouts
Study: 14585524
Drug: Estradiol Hemihidrate
Normalized name: estradiol hemihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol Hemihidrate 2 mg + Norethindron Asetate 1 mg/day
Study: 14585524
Drug: 17 beta-estradiol
Normalized name: 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol 2 mg/day
Study: 14585524
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pre-therapy values)
Study: 11872997
Drug: Dronabinol 2.5
Normalized name: dronabinol 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol 2.5 mg capsules
Study: 10194038
Drug: Intravenous tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tacrolimus followed by oral therapy and mycophenolate mofetil (MMF) with a fixed dose of 2 g/day in Phase I and adjusted doses in Phase II based on mycophenolic acid (MPA) plasma levels.
Study: 31932567
Drug: Risk factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factors affecting delirium (e.g., age over 65, unconsciousness, dependent activities, abnormal vital signs, pressure ulcer risk, enteral nutrition, use of restraint)
Study: 23653274
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg fasting and 5 mg at bedtime)
Study: 23964473
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's Wort extract WS 5570, 600 mg once daily for 8 to 10 weeks
Study: 23964473
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's Wort extract WS 5570, 600 mg once daily
Study: 8174440
Drug: Omeprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (60 mg daily)
Study: 8174440
Drug: Pancreatin monotherapy
Normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatin monotherapy
Study: 22318648
Drug: Free consumption
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free consumption of fruits and vegetables (less than 75 mg phenylalanine per 100 g)
Study: 22318648
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (accounting for protein from fruits and vegetables)
Study: 16995860
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg twice daily for 6 weeks
Study: 10750566
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (menatetrenone) 45 mg/day orally
Study: 10750566
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without treatment)
Study: 3886024
Drug: L-tryptophan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (12 g/day)
Study: 3886024
Drug: L-tryptophan (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (continued treatment)
Study: 3886024
Drug: Placebo (switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (switched from L-tryptophan)
Study: 3886024
Drug: L-tryptophan (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (increased synthesis of 5-hydroxytryptamine)
Study: 3886024
Drug: L-tryptophan (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (in men)